Will Antonio Gracias acquire a controlling stake in Lykos Therapeutics by June 30, 2025?
Yes • 50%
No • 50%
Official announcements from Lykos Therapeutics or financial news outlets
Antonio Gracias Leads Hostile Takeover Bid for MDMA Startup Lykos Therapeutics, Backed by $100 Million Funding and Rick Doblin
Jan 10, 2025, 05:38 AM
Lykos Therapeutics, a startup focused on MDMA-based therapies, is facing a hostile takeover bid led by Antonio Gracias, an early investor in Tesla. Gracias, who is allied with Maps founder Rick Doblin, aims to secure a controlling stake in the company with the support of Jeff Aronin, a prominent figure in the pharmaceutical industry and founder of Paragon Biosciences. The bid comes amid ongoing challenges for Lykos, including issues related to sexual abuse by therapists during clinical trials, which were highlighted during a recent FDA review. Additionally, Helena, which spearheaded Lykos's $100 million funding round last year, is reportedly seeking to sever ties between Lykos and the non-profit organization Maps, holding veto rights over any potential deal.
View original story
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No majority stakeholder • 25%
Current majority stakeholder • 25%
Switch • 25%
New investor • 25%
Lightspeed Venture Partners • 25%
Google • 25%
Other • 25%
Sequoia Capital • 25%
Other • 25%
Another major VC firm • 25%
A new investor • 25%
Another existing investor • 25%
Amazon • 25%
Lightspeed Venture Partners • 25%
Amazon • 25%
Another major VC firm • 25%
Other • 25%
Lightspeed Venture Partners • 25%
Other • 25%
Lightspeed Venture Partners • 25%
Amazon • 25%
Another tech giant • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No significant changes • 25%
Other leadership changes • 25%
CEO change • 25%
Board reshuffle • 25%
Revised partnership terms • 25%
Collaboration continues • 25%
No clear outcome • 25%
Formal separation • 25%